NGAL (Neutrophil Gelatinase-Associated Lipocalin) as an early biomarker of nephropathy in patients with type 2 diabetes

References

• Lim A. Diabetic nephropathy - complications and treatment. Int J Nephrol Renovasc Dis. 2014;7:361–381. doi: 10.2147/ijnrd.s40172
   PubMedGoogle Scholar
• Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302–308. doi: 10.1681/ASN.2012070718
   PubMed Web of Science ®Google Scholar
• Robles NR, Villa J, Felix FJ, et al. Non-proteinuric diabetic nephropathy is the main cause of chronic kidney disease: results of a general population survey in Spain. Diabetes Metab Syndr. 2017; 11(Suppl 2):S777–s81. doi: 10.1016/j.dsx.2017.05.016
   PubMedGoogle Scholar
• Boronat M, García-Cantón C, Quevedo V, et al. Non-albuminuric renal disease among subjects with advanced stages of chronic kidney failure related to type 2 diabetes mellitus. Ren Fail. 2014;36(2):166–170. doi: 10.3109/0886022x.2013.835266
   PubMed Web of Science ®Google Scholar
• Mancini M, Masulli M, Liuzzi R, et al. Renal duplex sonographic evaluation of type 2 diabetic patients. J Ultrasound Med. 2013;32(6):1033–1040. doi: 10.7863/ultra.32.6.1033
   PubMed Web of Science ®Google Scholar
• Budhiraja P, Thajudeen B, Popovtzer M. Absence of albuminuria in type 2 diabetics with classical diabetic nephropathy: clinical pathological study. J Biomed Sci Eng. 2013;6:20–25. doi: 10.4236/jbise.2013.65A005
   Google Scholar
• Robles NR, Villa J, Gallego RH. Non-proteinuric diabetic nephropathy. J Clin Med. 2015;4(9):1761–1773. doi: 10.3390/jcm4091761
   PubMed Web of Science ®Google Scholar
• Porrini E, Ruggenenti P, Mogensen CE, et al. Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2015;3(5):382–391. doi: 10.1016/s2213-8587(15)00094-7
   PubMed Web of Science ®Google Scholar
• Halimi JM. The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients. Diabetes Metab. 2012; 38(4):291–297. doi: 10.1016/j.diabet.2012.04.001
   PubMed Web of Science ®Google Scholar
• Esteghamati A, Arefzadeh A, Zandieh A, et al. Comparison of osteoprotegerin and vascular endothelial growth factor in normoalbuminuric Type 1 diabetic and control subjects. J Endocrinol Invest. 2013;36(7):474–477. doi: 10.1007/bf03347110
   PubMed Web of Science ®Google Scholar
• Lewis JR, Lim WH, Ueland T, et al. Elevated circulating osteoprotegerin and renal dysfunction predict 15-year cardiovascular and all-cause mortality: a prospective study of elderly women. PLoS One. 2015;10(7):e0134266. doi: 10.1371/journal.pone.0134266
   PubMed Web of Science ®Google Scholar
• Brachemi S, Bollée G. Renal biopsy practice: what is the gold standard? World J Nephrol. 2014;3(4):287–294. doi: 10.5527/wjn.v3.i4.287
   PubMedGoogle Scholar
• Satirapoj B, Nast CC, Adler SG. Novel insights into the relationship between glomerular pathology and progressive kidney disease. Advances in chronic kidney disease. 2012;19(2):93–100.
   Google Scholar
• Koye DN, Magliano DJ, Reid CM, et al. Risk of Progression of nonalbuminuric CKD to end-stage kidney disease in people with diabetes: the CRIC (chronic renal insufficiency cohort) study. Am J Kidney Dis. 2018;72(5):653–661. doi: 10.1053/j.ajkd.2018.02.364
   PubMed Web of Science ®Google Scholar
• Cloud-clone Corp. Human neutrophil gelatinase-associated lipocalin (NGAL) ELISA kit guide. 2021.
   Google Scholar
• Nazar CM. Diabetic nephropathy; principles of diagnosis and treatment of diabetic kidney disease. J Nephropharmacol. 2014;3(1):15–20.
   PubMedGoogle Scholar
• Peres LA, da Cunha AD Jr., Assumpção RA, et al. Evaluation of the cisplatin nephrotoxicity using the urinary Neutrophil Gelatinase-associated LipocaliN (NGAL) in patients with head and neck cancer. J Brasileiro de Nefrologia: ‘Orgao Oficial de Sociedades Brasileira E Latino-Americana de Nefrologia. 2014;36(3):280–288. doi: 10.5935/0101-2800.20140041
   PubMedGoogle Scholar
• Tkaczyk M, Tomczyk D, Jander A, et al. Glomerular filtration decrease after diagnostic cardiac catheterisation in children with congenital cardiac malformation - the role of serum creatinine, cystatin C, neutrophil gelatinase and urine output monitoring. Postepy w kardiologii interwencyjnej = Advances in interventional cardiology. 2018;14(1):67–74. doi: 10.5114/aic.2018.74357
   Google Scholar
• Mahfouz MH, Assiri AM, Mukhtar MH. Assessment of Neutrophil gelatinase-associated lipocalin (NGAL) and retinol-binding protein 4 (RBP4) in Type 2 diabetic patients with nephropathy. Biomark Insights. 2016;11:31–40. doi: 10.4137/bmi.s33191
   PubMed Web of Science ®Google Scholar
• Siddiqui K, Joy SS, George TP, et al. Potential role and excretion level of urinary transferrin, KIM-1, RBP, MCP-1 and NGAL markers in diabetic nephropathy. diabetes, metabolic syndrome and obesity: targets and therapy. 2020;13:5103–5111. doi: 10.2147/dmso.s282166
   Google Scholar
• Forghani MS, Khezrian F, Khezrian S, et al. Urinary Neutrophil Gelatinase-associated LipocaliN in early detection of diabetic nephropathy; a pilot study. J Renal Injury Prev. 2020;9(3):e23. doi: 10.34172/jrip.2020.23
   Web of Science ®Google Scholar
• Kaul A, Behera MR, Rai MK, et al. Neutrophil Gelatinase-associated lipocalin: as a predictor of early diabetic nephropathy in type 2 diabetes mellitus. Indian J Nephrol. 2018;28(1):53–60. doi: 10.4103/ijn.IJN_96_17
   PubMed Web of Science ®Google Scholar
• Fathimah M, Alicezah MK, Thevarajah M. Neutrophil Gelatinase-Associated Lipocalin (NGAL): an early marker for diabetic nephropathy. Int J Diabetes Dev Ctries. 2012;32(1):19–24. doi: 10.1007/s13410-011-0061-z
   Web of Science ®Google Scholar
• Morii T, Fujita H, Narita T, et al. Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J Diabetes Complications. 2003;17(1):11–15. doi: 10.1016/s1056-8727(02)00176-9
   PubMed Web of Science ®Google Scholar
• Kim SS, Song SH, Kim IJ, et al. Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients. Diabetes Res Clin Pract. 2012;97(2):251–257. doi: 10.1016/j.diabres.2012.02.019
   PubMed Web of Science ®Google Scholar
• Nielsen SE, Sugaya T, Hovind P, et al. Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care. 2010;33(6):1320–1324. doi: 10.2337/dc09-2242
   PubMed Web of Science ®Google Scholar